Clinical Trial Update: Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on cabozantinib (XL184) in relapsed or refractory multiple myeloma reporting Phase 1/2 results; results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• cabozantinib (cabozantinib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Relapsed or Refractory Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-08-30